Pavmed Inc (PAVM)

$0.86

+0.01

(+1.06%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Pavmed Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.04M → 1.01M (in $), with an average decrease of 3.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -14.03M → -15.21M (in $), with an average decrease of 8.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 46.6% return, outperforming this stock by 132.3%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 76.8% return, outperforming this stock by 175.8%

Performance

  • $0.83
    $0.95
    $0.86
    downward going graph

    3.37%

    Downside

    Day's Volatility :12.5%

    Upside

    9.45%

    downward going graph
  • $0.60
    $9.00
    $0.86
    downward going graph

    30.24%

    Downside

    52 Weeks Volatility :93.33%

    Upside

    90.44%

    downward going graph

Returns

PeriodPavmed IncSector (Health Care)Index (Russel 2000)
3 Months
-55.96%
6.1%
0.0%
6 Months
-74.16%
4.9%
0.0%
1 Year
-85.66%
13.6%
0.0%
3 Years
-99.02%
14.3%
-22.5%

Highlights

Market Capitalization
7.5M
Book Value
- $7.71
Earnings Per Share (EPS)
-9.0
PEG Ratio
0.0
Wall Street Target Price
9.75
Profit Margin
0.0%
Operating Margin TTM
-1389.7%
Return On Assets TTM
-76.1%
Return On Equity TTM
-1358.06%
Revenue TTM
3.0M
Revenue Per Share TTM
0.39
Quarterly Revenue Growth YOY
126.49999999999999%
Gross Profit TTM
-3.2M
EBITDA
-59.6M
Diluted Eps TTM
-9.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.51
EPS Estimate Next Year
-3.68
EPS Estimate Current Quarter
-1.67
EPS Estimate Next Quarter
-1.56

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Pavmed Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1033.72%

Current $0.86
Target $9.75

Technicals Summary

Sell

Neutral

Buy

Pavmed Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pavmed Inc
Pavmed Inc
-19.05%
-74.16%
-85.66%
-99.02%
-94.6%
Stryker Corporation
Stryker Corporation
-2.4%
8.05%
13.44%
27.62%
63.8%
Boston Scientific Corp.
Boston Scientific Corp.
-0.67%
28.28%
46.57%
76.8%
81.99%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
5.79%
25.42%
-0.27%
-13.09%
45.49%
Abbott Laboratories
Abbott Laboratories
-0.19%
-8.55%
-2.5%
-12.31%
24.14%
Medtronic Plc
Medtronic Plc
-5.06%
-10.7%
-10.85%
-39.1%
-21.34%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pavmed Inc
Pavmed Inc
NA
NA
0.0
-6.51
-13.58
-0.76
NA
-7.71
Stryker Corporation
Stryker Corporation
38.47
38.47
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
64.8
64.8
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
40.02
40.02
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.2
32.2
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
27.92
27.92
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pavmed Inc
Pavmed Inc
Buy
$7.5M
-94.6%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
63.8%
38.47
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$113.4B
81.99%
64.8
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$56.0B
45.49%
40.02
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.3B
24.14%
32.2
13.96%
Medtronic Plc
Medtronic Plc
Buy
$98.8B
-21.34%
27.92
11.36%

Institutional Holdings

  • First Manhattan Co. LLC

    4.51%
  • Vanguard Group Inc

    3.19%
  • BlackRock Inc

    0.79%
  • Geode Capital Management, LLC

    0.67%
  • Valeo Financial Advisors, LLC

    0.22%
  • State Street Corporation

    0.22%

Company Information

pavmed is a groundbreaking medical device company bringing innovative medical technologies from concept to commercialization with unprecedented speed and efficiency. led by three accomplished medical device entrepreneurs and organized to conceive, develop and commercialize a diversified pipeline of innovative products we believe address unmet clinical needs, our goal is to enhance and accelerate value creation by employing a business model focused on capital and time efficiency.

Organization
Pavmed Inc
Employees
107
CEO
Dr. Lishan Aklog M.D.
Industry
Health Technology

FAQs